A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).

• Status: Active, not recruiting
• Trial end date: 2024-12-31

Summary

The goal of this clinical trial is to evaluate the safety and efficacy of PLB1001 Enteric Capsules in the treatment of PTPRZ1-MET fusion gene positive recurrent secondary glioblastoma. The main questions it aims to answer are:

1. To evaluate overall survival (OS) in the treatment of secondary glioblasts with positive recurrence of PTPRZ1-MET (ZM) fusion gene by PLB1001 Enteric Capsules.

2. To evaluate if it is safety and tolerant in the treatment of secondary glioblasts with positive recurrence of PTPRZ1-MET (ZM) fusion gene by PLB1001 Enteric Capsules.

Participants will

1. Be given PLB1001 300mg BID,oral who were randomly assigned in test group.

2. Be given Temozolomide capsules ,oral, who were randomly assigned in control group.

3. Be given EP, ivgtt, who were randomly assigned in control group.

• Phase: Phase 2/Phase 3

Details

• Lead Sponsor: Beijing Pearl Biotechnology Limited Liability Company
• Treatments: Etoposide; Temozolomide